High-Risk CD117-Positive Gastrointestinal Stromal Tumor of the Colon in a 12-Year-Old Girl: Adjuvant Treatment with Imatinib Mesylate

Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the alimentary tract rarely observed in children. The treatment of choice for GIST is surgical resection. Although the prognosis of GISTs with low malignant potential is excellent, high-malignant-potential GISTs have a high rate of re...

Full description

Saved in:
Bibliographic Details
Published in:Tumori 2012-03, Vol.98 (2), p.59-62
Main Authors: Okur, Arzu, Oguz, Aynur, Karadeniz, Ceyda, Pinarli, Faruk Guclu, Ozen, Onur, Ekinci, Ozgür
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Benzamides
Biomarkers, Tumor - analysis
Chemotherapy, Adjuvant
Child
Colonic Neoplasms - chemistry
Colonic Neoplasms - diagnosis
Colonic Neoplasms - drug therapy
Colonic Neoplasms - pathology
Colonic Neoplasms - surgery
Female
Gastrointestinal Stromal Tumors - chemistry
Gastrointestinal Stromal Tumors - diagnosis
Gastrointestinal Stromal Tumors - drug therapy
Gastrointestinal Stromal Tumors - pathology
Gastrointestinal Stromal Tumors - surgery
Humans
Imatinib Mesylate
Piperazines - therapeutic use
Protein Kinase Inhibitors - therapeutic use
Protein-Tyrosine Kinases - antagonists & inhibitors
Proto-Oncogene Proteins c-kit - analysis
Pyrimidines - therapeutic use
Risk Assessment
Risk Factors
Tomography, X-Ray Computed
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the alimentary tract rarely observed in children. The treatment of choice for GIST is surgical resection. Although the prognosis of GISTs with low malignant potential is excellent, high-malignant-potential GISTs have a high rate of recurrence. Prognostic factors such as tumor size, mitotic rate and presence of metastases may provide an indication for adjuvant imatinib mesylate (IM) treatment. Here we present a young patient with a large GIST with high-risk features who is in complete remission after surgical excision and adjuvant IM treatment. This patient is the only colon-located CD117-positive case where IM was administered. The exact indications as well as the optimal dose and duration of IM need to be clarified with the contribution of new cases and the growing experience of this rare disease.
ISSN:0300-8916
2038-2529
DOI:10.1177/030089161209800226